U.S., May 10 -- ClinicalTrials.gov registry received information related to the study (NCT06963541) titled 'IL-40 and IL-41 Levels in Sepsis, Septic Shock, and Healthy Individuals' on April 30.
Brief Summary: This study aims to investigate the blood levels of two recently identified immune-related proteins, Interleukin-40 (IL-40) and Interleukin-41 (IL-41), in patients with sepsis and its more severe form, septic shock. Sepsis is a serious condition caused by an abnormal immune response to infection, which can lead to organ dysfunction. Septic shock represents an advanced stage of sepsis, characterized by significantly higher mortality risk.
IL-40 and IL-41 are newly discovered molecules that are thought to play important roles in the imm...